Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Veracyte Inc (NQ: VCYT ) 23.50 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 23.50 Bid (Size) 23.30 (9) Ask (Size) 23.47 (4) Prev. Close 23.50 Today's Range 23.50 - 23.50 52wk Range 18.63 - 29.40 Shares Outstanding 67,473,870 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024 July 17, 2024 From Veracyte, Inc. Via Business Wire Trading SMID Biotech Stocks In A Volatile Market July 01, 2024 Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... Via Talk Markets Performance YTD -14.23% -14.23% 1 Month +2.44% +2.44% 3 Month +18.51% +18.51% 6 Month -11.22% -11.22% 1 Year -14.67% -14.67% More News Read More Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness June 10, 2024 Via Benzinga A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts May 08, 2024 Via Benzinga Recap: Veracyte Q4 Earnings February 22, 2024 Via Benzinga Earnings Outlook For Veracyte February 21, 2024 Via Benzinga Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors June 03, 2024 From Veracyte, Inc. Via Business Wire Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer May 22, 2024 From Veracyte, Inc. Via Business Wire Veracyte to Participate in Upcoming Investor Conferences May 15, 2024 From Veracyte, Inc. Via Business Wire VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Veracyte Announces First Quarter 2024 Financial Results May 07, 2024 From Veracyte, Inc. Via Business Wire 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding May 06, 2024 From Veracyte, Inc. Via Business Wire Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 April 22, 2024 From Veracyte, Inc. Via Business Wire New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance April 22, 2024 From Veracyte, Inc. Via Business Wire Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 April 16, 2024 From Veracyte, Inc. Via Business Wire Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally February 28, 2024 Via Benzinga Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold February 27, 2024 Via Benzinga Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines February 27, 2024 From Veracyte, Inc. Via Business Wire Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed February 26, 2024 Via Benzinga 7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff February 26, 2024 Via InvestorPlace Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results February 22, 2024 From Veracyte, Inc. Via Business Wire Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference February 21, 2024 From Veracyte, Inc. Via Business Wire Earnings Scheduled For February 22, 2024 February 22, 2024 Via Benzinga Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 February 08, 2024 From Veracyte, Inc. Via Business Wire Veracyte Completes Acquisition of C2i Genomics February 06, 2024 From Veracyte, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
